Objective: To assess the effects of hypnotics on prefrontal cortex activity in healthy subjects using near-infrared spectroscopy (NIRS) in a double-blind, placebocontrolled crossover trial.
variety of psychiatric disorders, including major depressive disorder, bipolar, panic, eating, and attention deficit hyperactivity disorders, schizophrenia, Alzheimer's dementia, and alcoholism (Kameyama et al., 2006; Katayama et al., 2014; Schecklmann et al., 2007; Suda et al., 2010; Suto, Fukuda, Ito, Uehara, & Mikuni, 2004) , thereby showing promise as a potential differential diagnostic tool in psychiatric clinical practice (Takizawa et al., 2014) .
In addition to the influences attributable to specific diseases, several factors, including age, sex, and sleepiness, can influence changes in Hb concentration in NIRS (Kameyama, Fukuda, Uehara, & Mikuni, 2004; Suda et al., 2008) . For example, sleep disturbance is typically associated with psychiatric patients (Wulff, Gatti, Wettstein, & Foster, 2010) , and sleep complaints have been shown to reduce prefrontal activation as measured by NIRS in patients with major depression (Nishida et al., 2017) . We have previously described that acute and subchronic deficient sleep may reduce peak oxyhemoglobin (oxy-Hb) concentration in the lateral frontal lobes (Miyata et al., 2010; Miyata, Noda, et al., 2015) and that NIRS measurements are differentially affected by mirtazapine and trazodone (Kohmura et al., 2013) , which are sedating antidepressants commonly used to treat chronic insomnia in the United States. In addition, antidepressants have recently been shown to have a dose-dependent effect on NIRS signals (Takamiya et al., 2017) . Although the effects of hypnotics on brain function have been investigated in terms of functional brain imaging techniques such as positron emission tomography (PET) (Mintzer et al., 2006) and functional magnetic resonance imaging (fMRI) (Licata, Lowen, Trksak, Maclean, & Lukas, 2011) , to our knowledge, no studies have clarified the effects of hypnotics in terms of NIRS measurements.
In many European countries, benzodiazepine receptor agonists are commonly prescribed to treat insomnia (Clay, Falissard, Moore, & Toumi, 2013) . These drugs are most prescribed for patients with insomnia in Japan (Report of the International Narcotics Control Board for 2015, 2015). However, these hypnotics frequently lead to residual morning sedation and cognitive impairments, including impaired driving performance (Barker, Greenwood, Jackson, & Crowe, 2004; Takahashi et al., 2010; Vermeeren, 2004) .
Ramelteon, a selective melatonin receptor (MT1/MT2) agonist, promotes sleep without significantly interacting with GABA-benzodiazepine and muscarinic receptors and has been reported to have minimal effects on sedation and cognitive function (Johnson, Suess, & Griffiths, 2006) ; however, similar to benzodiazepine receptor agonists, ramelteon has also been shown to impair driving performance (Mets et al., 2011; .
Although the differential effects of these hypnotics on brain function can be estimated according to their pharmacological profiles, to our knowledge, they have not been demonstrated simultaneously.
Therefore, the objective of the present study was to examine the effects of triazolam and ramelteon on brain activity in healthy volunteers using multichannel NIRS. We chose triazolam for short 
| Drug administration and study design
A double-blind, placebo-controlled crossover design was used in which each participant was assigned to receive three different treatments (8-mg ramelteon, 0.125-mg triazolam, and placebo in identical capsules) across three different treatment sessions according to a randomization schedule. Participants were randomized to predetermined and counterbalanced regimen in order of enrollment.
The doses selected were based on generally recommended clinical starting dose. Each treatment session was separated by a washout period of at least 7 days. Each participant was administered one of the three test drugs after baseline NIRS assessment at 09:00. The NIRS assessments were repeated at 1 and 4 hr of postdosing. All participants then completed a verbal fluency task while their prefrontal cortical activity was measured using an NIRS recorder (FOIRE-3000; Shimadzu, Kyoto, Japan). In addition, the Stanford Sleepiness Scale (SSS) was used to assess subjective sleepiness at the time of the examination. The SSS (one item) is a seven-point, self-reporting measure of alertness with proven sensitivity (Hoddes, Zarcone, Smythe, Phillips, & Dement, 1973) . Higher value means increased sleepiness.
| Activation task
Changes in Hb concentration were measured while participants completed a letter-version verbal fluency task that has been administered in many previous studies (Kameyama et al., 2004; Kameyama et al., 2006; Katayama et al., 2014; Kohmura et al., 2013; Suda et al., 2008; Suda et al., 2010; Suto et al., 2004) . Throughout the measurements, the participants remained seated on a comfortable chair with their eyes open in a sunlit room. Regarding the task, the participants were given oral instructions to generate as many common nouns (excluding proper nouns and repetitions) as possible beginning with the Japanese syllables "a," "ki," "ha," "to," "se," "o," "i," "no," or "ta."
Stimulus syllables were counterbalanced for each treatment condition.
In total, all participants performed a 30-s pretask, a 60-s verbal fluency task, and 60-s posttask. Performance was judged on the basis of the number of words generated during the verbal fluency task. The participants were instructed to repeat the vowels "a," "i," "u," "e," and "o" during both the pretask and posttask periods as the Japanese counterparts of A, B, and C in English (Kameyama et al., 2004) .
Practice sessions were conducted before the main examinations when the NIRS responses were actually recorded until the experimenter judged that the participants fully understood the procedure.
| NIRS measurements
Relative changes in oxy-Hb and deoxygenated hemoglobin (deoxy-Hb)
were measured using a functional NIRS system (FOIRE-3000; Shimadzu, Kyoto, Japan) at three different wavelengths (780, 805, and 830 nm) . An NIRS shell with 3 × 5 arrays of light emitters and detectors (distance between probes: 3 cm), which can measure the relative concentrations of oxy-Hb and deoxy-Hb at 22 different measurement points in a 9 × 15 cm area, was used ( Figure 1 ).
According to the International 10-20 system used in electroencephalography, the NIRS shell was placed over the frontal region, with the lowest probes positioned along the Fp1-2 line (Okamoto et al., 2004) . The NIRS channels 1-4, 6-8, 10-13, 15-17, and 19-22 were roughly localized on superior frontal gyrus, and channels 5, 9, 14, and 18 were roughly localized on middle frontal gyrus. Positions of NIRS channels were shown on International 10-20 system (Kato et al., 2018) (Figure 2 ).
| Data analysis and statistics
Next, oxy-Hb values in the 22 channels located above the prefrontal cortex were analyzed. We focused on changes in oxy-Hb concentration as they are thought to reflect cognitive activation more directly than changes in deoxy-Hb, based on a stronger correlation with blood-oxygenation level-dependent signals as measured by fMRI (Strangman, Culver, Thompson, & Boas, 2002) . Near-infrared light absorption was measured using a temporal resolution of 0.1 s.
Waveforms of oxy-Hb changes were acquired across participants during the task for all 22 channels. NIRS data containing motion artifacts as determined by close observation were excluded from further statistical analysis (data were excluded from two participants in total).
A low-pass filter with a high cutoff of 0.1 Hz was used to exclude short-term motion artifacts, and oxy-Hb data showing low signal-tonoise ratios in channels 1-5, 7, 9, 14, 16, and 18-22 were excluded from further analysis. Next, oxy-Hb concentrations during the task and posttask periods were averaged. The pretask baseline value was FIGURE 1 Placement of near-infrared spectroscopy shells No correlations were observed between the numbers of words correctly generated and changes in oxy-Hb concentration.
| SSS scores
The SSS scores are summarized in Table 1 . A significant drug effect was observed, F (2, 77) = 9.53, p < 0.001. The post hoc test showed that SSS scores under the ramelteon and triazolam conditions were significantly greater compared with the placebo condition (both p = 0.03) at 1 hr of postdosing. No correlations were observed between SSS scores and changes in oxy-Hb concentration except for channel 11 (ρ = −0.18, p = 0.028).
| NIRS response
No significant drug × time interaction or drug effect was found during the task period. Regarding the posttask period, significant drug effects were observed in channels 8, F (2, 120) = 3.55, p = 0.03; 11, F (2, 120) = 2.46, p = 0.09; 12, F (2, 120) = 5.65, p = 0.005; 
| DISCUSSION
In the present study, we measured changes in oxy-Hb concentration using NIRS to examine the effects of two different hypnotics on cortical activity during the performance of a verbal fluency task. Although both ramelteon and triazolam yielded greater subjective sleepiness, triazolam resulted in decreased brain activity compared with placebo in some channels during the posttask period. The differential effects of ramelteon and triazolam, as well as antidepressants, on brain activity should be considered (Kohmura et al., 2013; Takamiya et al., 2017 ) when performing NIRS.
We assumed that the superior frontal gyrus would be activated in relation to changes in oxy-Hb concentration (Tsuzuki et al., 2007) .
Although no difference in activation was observed during the task period among the three drug conditions, triazolam significantly reduced brain activity, mainly in the central area of the prefrontal cortex during the posttask period. Triazolam reduced activation in the prefrontal cortex during a verbal learning task in a previous PET study (Mintzer et al., 2006) and zolpidem, a benzodiazepine receptor agonist similar to triazolam, reduced activation in the occipital cortex during a checkerboard task in a previous fMRI study (Licata et al., 2011) . However, no studies have examined the effects of hypnotics on brain blood flow as measured by NIRS during a TABLE 1 Number of words correctly generated and subjective sleepiness (mean ± SD) used in the present study, can cause cortical dysfunction (Urata et al., 1996) . These past findings regarding the decreased prefrontal cortex activity associated with triazolam are consistent with those of the present study.
On the other hand, the effect of ramelteon on brain activity has not been examined. To the best of our knowledge, this is the first study to elucidate the effects of ramelteon on brain activity during a cognitive task. Ramelteon had little effect on prefrontal activity during both the task and posttask periods, similar to that of the placebo. Previous studies using NIRS demonstrated that subjective sleepiness decreased prefrontal activity during a verbal fluency task (Miyata, Noda, et al., 2015; Suda et al., 2008) . In the present study, both triazolam and ramelteon increased subjective sleepiness; however, the extent of sleepiness was small compared with previous studies, meaning that it may contribute little to brain activity. In addition, tend to reduce oxy-Hb concentrations below a significant level (Kono et al., 2007) . Third, to examine carefully the effects of drug and adverse reaction on brain function, the initial low doses of both triazolam and ramelteon were acutely administered to the participants.
Nevertheless, we have to recognize that these doses pose a methodological problem because the initial low doses may be insufficient to affect brain activity. Finally, all participants in the present research were healthy men who were not currently taking any drugs. On the whole, most patients with psychiatric disorders are using alternative pharmacotherapies, so extracting particular responses to a single specific administered drug would be difficult. In addition, hormonal changes related to the menstrual cycle can affect cognitive function (Hampson, 1990; Maki, Rich, & Rosenbaum, 2002; Phillips & Sherwin, 1992) , thereby influencing performance in cognitive tasks. Changes in brain function in patients with psychiatric disorders could vary from those in healthy participants, and sensitivity and response to a drug might differ in women and the elderly. Therefore, the results of this study, which comprised only healthy participants, might not be just as valid for patients with psychiatric disorders. 
